Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00000628 | A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine | PHASE1 | COMPLETED | 27 | — | — | - | - | Jul 30, 2008 | 5 | United States |
| Name | Type | Description |
|---|---|---|
| L-697,661 | DRUG | - |
| Zidovudine | DRUG | - |
Inclusion Criteria Patients must have: * HIV infection. Prior Medication: Included: * Patients in Part 1 must have received no previous zidovudine (AZT) or a stable dose of at least 500 mg/day without evidence of toxicity. * Patients in Part 2 must have received no previous AZT or = or \> 300 mg...